KAICOロゴマーク
Core Technologyイメージ画像

Core Technology

At KAICO, we use the "silkworm-baculovirus expression system" as our core technology, which is based on the use of the Kyushu University's proprietary baculovirus genome and expertise in gene and protein design. This allows us to express target proteins within the silkworm's body.
Utilizing highly productive silkworm strains uniquely possessed by Kyushu University, and our proprietary gene design expertise, our recombinant protein production platform can produce high-quality proteins that are difficult to produce in other expression systems.
Core Technologyイメージ画像
play button
Core Technologyイメージ画像

Service & Product

Using our silkworm-baculovirus expression system, we provide trial expression services for customized proteins, supporting our customers' research and development efforts. After contract expression, we also offer sales of customized reagents.
At KAICO, we utilize the recombinant proteins expressed using our core silkworm-baculovirus expression technology to develop our own proprietary supplements as well as animal and human vaccines.
Core Technologyイメージ画像

COMPANY

KAICO is a bio-startup originating from Kyushu University, with the goal of delivering silkworm-produced pharmaceuticals and vaccines to the world, based on the proteins generated through our proprietary "silkworm-baculovirus expression system".